The Efficacy and Safety of Bempedoic Acid Compared to Existing Hypolipidemic Agents-A Systematic Review

Background-Lipid disorders are prevalent worldwide, necessitating effective and safe treatments. Bempedoic acid has emerged as an alternative lipid-lowering agent, particularly for statin-intolerant patients. This study systematically reviews its efficacy and safety profile compared to traditional hypolipidemic agents. Methods- A comprehensive review of clinical trials analyzing Bempedoic acid's effects on LDL-C reduction and safety was conducted. Studies comparing its mechanism of action with statins and other lipid-lowering drugs were included. Results- Bempedoic acid significantly reduces LDL-C levels, particularly in patients who are intolerant to statins or require additional lipid control. Its mechanism of action, through ATP-citrate lyase inhibition, distinguishes it from statins and offers a potential therapeutic advantage. Clinical findings indicate a favorable safety profile, with lower incidences of muscle-related side effects compared to statins. Conclusions- Bempedoic acid represents a promising adjunct or alternative therapy for dyslipidemia management. Its unique mechanism of action and efficacy suggest its potential role in personalized lipid-lowering strategies, particularly for patients requiring statin-free options. Future research should focus on long-term cardiovascular outcomes and optimal combination therapies involving Bempedoic acid.